Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

Summary

The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.

Timeline

Start

2026-07

Primary completion

2028-12

Completion

2029-12

Drugs

Indications